Publication of Groundbreaking Study on Ultra-Sensitive Molecular Residual Disease Detection in EMBO Molecular Medicine

We are proud to announce the publication of our latest research titled,"Ultra-sensitive molecular residual disease detection through whole genomesequencing with single-read error correction," in the prestigious journal EMBOMolecular Medicine. This peer-reviewed study showcases the breakthrough of AccuScan whole-genome sequencing (WGS) assay, designed for ultra-sensitive detection of minimal residual disease (MRD) in cancer patients.

The innovative AccuScan technology applies a unique combination of whole-genomesequencing and advanced error correction methods, enabling the detection of even the smallest traces of residual disease, with a limit of detectiondown to the parts-per-million (PPM) range. The technology significantly enhances both sensitivity and specificity,setting a new benchmark for MRD testing.

By leveraging intramolecularligation and rolling circle amplification, AccuScan enables highly efficient single-read errorcorrection, providing accurate genome-wide analysis of circulating tumor DNA(ctDNA) from post-treatment plasma samples. These advancements allow AccuScan to deliver reliable MRD status results while requiring only minimalamounts of DNA input.

"We are excited to share theseremarkable results that underscore the power of our AccuScan technology,"said Li Weng, Senior Vice President of R&D at AccuraGen and lead author ofthe study. "This publication in EMBO Molecular Medicine validatesour approach to MRD detection, and we are confident that AccuScan has thepotential to transform how residual disease is monitored in cancerpatients."

This study marks a major step forward in the company’smission to deliver cutting-edge oncology solutions that improve patientoutcomes.

The full study is available in the September2024 issue of EMBO Molecular Medicine. https://www.embopress.org/doi/full/10.1038/s44321-024-00115-0